GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

NCT04251117 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

HCC

Interventions

BIOLOGICAL: GNOS-PV02
BIOLOGICAL: INO-9012
DRUG: Pembrolizumab
DEVICE: CELLECTRA®2000 EP Device

Sponsor

Geneos Therapeutics